Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Footnote F1 (shares): At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation… Full note on SEC EDGAR
Footnote F1 (shares): At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation… Full note on SEC EDGAR
Footnote F1 (shares): At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation… Full note on SEC EDGAR
Footnote F1 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,085.00 to $1,085.60, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or… Full note on SEC EDGAR
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,086.28 to $1,087.06, inclusive.
Footnote F3 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,087.45 to $1,088.36, inclusive.
Footnote F4 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,088.50 to $1,089.32, inclusive.
Footnote F5 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,089.79 to $1,090.78, inclusive.
Footnote F6 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,090.88 to $1,091.51, inclusive.
Footnote F7 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,091.97 to $1,092.80, inclusive.
Footnote F8 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,093.41 to $1,093.61, inclusive.
Footnote F9 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,094.56 to $1,094.85, inclusive.
Footnote F10 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,095.71 to $1,095.89, inclusive.
Footnote F11 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,096.87 to $1,097.83, inclusive.
Footnote F12 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,097.87 to $1,098.82, inclusive.
Footnote F13 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,098.87 to $1,099.86, inclusive.
Footnote F14 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,099.88 to $1,100.85, inclusive.
Footnote F15 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,100.88 to $1,101.87, inclusive.
Footnote F16 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,101.88 to $1,102.87, inclusive.
Footnote F17 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,102.88 to $1,103.86, inclusive.
Footnote F18 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,103.88 to $1,104.87, inclusive.
Footnote F19 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,104.88 to $1,105.87, inclusive.
Footnote F20 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,105.88 to $1,106.87, inclusive.
Footnote F21 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,106.93 to $1,107.92, inclusive.
Footnote F22 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,107.93 to $1,108.92, inclusive.
Footnote F23 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,108.94 to $1,109.91, inclusive.
Footnote F24 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,110.00 to $1,110.94, inclusive.
Footnote F25 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,111.01 to $1,112.00, inclusive.
Footnote F26 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,112.03 to $1,113.00, inclusive.
Footnote F27 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,113.05 to $1,114.01, inclusive.
Footnote F28 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,114.05 to $1,115.00, inclusive.
Footnote F29 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,115.11 to $1,116.07, inclusive.
Footnote F30 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,116.15 to $1,117.11, inclusive.
Footnote F1 (shares): At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation… Full note on SEC EDGAR
Footnote F1 (shares): At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation… Full note on SEC EDGAR
Footnote F1 (shares): At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation… Full note on SEC EDGAR
Footnote F1 (shares): At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation… Full note on SEC EDGAR
Footnote F1 (shares): At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation… Full note on SEC EDGAR
Footnote F1 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,073.78 to $1,074.77, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or… Full note on SEC EDGAR
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,075.50 to $1,076.47, inclusive.
Footnote F3 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,077.64 to $1,078.38, inclusive.
Footnote F4 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,078.84 to $1,079.52, inclusive.
Footnote F5 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,080.10 to $1,081.00, inclusive.
Footnote F6 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,081.36 to $1,082.25, inclusive.
Footnote F7 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,082.82 to $1,083.00, inclusive.
Footnote F8 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,084.50 to $1,085.45, inclusive.
Footnote F9 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,085.50 to $1,086.45, inclusive.
Footnote F10 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,086.50 to $1,087.49, inclusive.
Footnote F11 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,087.50 to $1,088.48, inclusive.
Footnote F12 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,088.50 to $1,089.47, inclusive.
Footnote F13 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,089.51 to $1,090.46, inclusive.
Footnote F14 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,090.57 to $1,091.55, inclusive.
Footnote F15 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,091.58 to $1,092.57, inclusive.
Footnote F16 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,092.58 to $1,093.57, inclusive.
Footnote F17 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,093.58 to $1,094.53, inclusive.
Footnote F18 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,094.65 to $1,095.32, inclusive.
Footnote F19 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,095.86 to $1,096.70, inclusive.
Footnote F20 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,096.87 to $1,097.86, inclusive.
Footnote F21 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,097.87 to $1,098.84, inclusive.
Footnote F22 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,098.87 to $1,099.85, inclusive.
Footnote F23 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,099.87 to $1,100.83, inclusive.
Footnote F24 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,100.87 to $1,101.86, inclusive.
Footnote F25 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,101.87 to $1,102.86, inclusive.
Footnote F26 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,102.97 to $1,103.96, inclusive.
Footnote F27 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,103.97 to $1,104.96, inclusive.
Footnote F28 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,104.97 to $1,105.96, inclusive.
Footnote F29 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,105.99 to $1,106.98, inclusive.
Footnote F30 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,107.00 to $1,107.95, inclusive.
Footnote F1 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,068.00 to $1,068.99, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or… Full note on SEC EDGAR
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,069.00 to $1,069.98, inclusive.
Footnote F3 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,070.00 to $1,070.99, inclusive.
Footnote F4 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,071.05 to $1,072.00, inclusive.
Footnote F5 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,072.08 to $1,073.00, inclusive.
Footnote F6 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,073.44 to $1,074.02, inclusive.
Footnote F1 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,050.00 to $1,050.997, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company… Full note on SEC EDGAR
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,051.00 to $1,051.994, inclusive.
Footnote F3 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,052.00 to $1,052.96, inclusive.
Footnote F4 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,053.00 to $1,053.99, inclusive.
Footnote F5 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,054.00 to $1,054.99, inclusive.
Footnote F6 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,055.00 to $1,055.969, inclusive.
Footnote F7 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,056.00 to $1,056.99, inclusive.
Footnote F8 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,057.00 to $1,057.97, inclusive.
Footnote F9 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,058.022 to $1,059.005, inclusive.
Footnote F10 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,059.034 to $1,060.032, inclusive.
Footnote F11 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,060.037 to $1,061.036, inclusive.
Footnote F12 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,061.039 to $1,062.022, inclusive.
Footnote F13 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,062.043 to $1,063.04, inclusive.
Footnote F14 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,063.051 to $1,064.042, inclusive.
Footnote F15 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,064.07 to $1,065.03, inclusive.
Footnote F16 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,065.118 to $1,066.00, inclusive.
Footnote F1 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,050.00 to $1,050.99, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or… Full note on SEC EDGAR
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,051.00 to $1,051.993, inclusive.
Footnote F3 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,052.00 to $1,052.999, inclusive.
Footnote F4 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,053.00 to $1,053.98, inclusive.
Footnote F5 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,054.00 to $1,054.998, inclusive.
Footnote F6 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,055.00 to $1,055.59, inclusive.
Footnote F1 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,050.00 to $1,050.999, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company… Full note on SEC EDGAR
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,051.00 to $1,051.999, inclusive.
Footnote F3 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,052.00 to $1,052.999, inclusive.
Footnote F4 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,053.00 to $1,053.993, inclusive.
Footnote F5 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,054.00 to $1,054.996, inclusive.
Footnote F6 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,055.00 to $1,055.54, inclusive.
Footnote F1 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,030.00 to $1,030.98, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or… Full note on SEC EDGAR
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,031.00 to $1,031.91, inclusive.
Footnote F3 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,032.02 to $1,033.01, inclusive.
Footnote F4 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,033.02 to $1,034.01, inclusive.
Footnote F5 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,034.02 to $1,035.01, inclusive.
Footnote F6 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,035.02 to $1,036.01, inclusive.
Footnote F7 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,036.02 to $1,037.01, inclusive.
Footnote F8 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,037.02 to $1,038.01, inclusive.
Footnote F9 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,038.03 to $1,038.94, inclusive.
Footnote F10 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,039.21 to $1,040.01, inclusive.
Footnote F1 (shares): At the election of the reporting person, the shares reported as acquired in this row have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation… Full note on SEC EDGAR
Footnote F1 (shares): At the election of the reporting person, the shares reported as acquired in this row have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation… Full note on SEC EDGAR
Footnote F1 (shares): At the election of the reporting person, the shares reported as acquired in this row have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation… Full note on SEC EDGAR
Footnote F1 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,030.00 to $1,030.99, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or… Full note on SEC EDGAR
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,031.00 to $1,031.75, inclusive.
See every LLY filing on record
These pages show the latest 90 of 179 Form 4 filings on record. The 7-day demo shows all 179, and sign-up brings you back to this table.
An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
ELI LILLY & Co (LLY) had 19 insider filings in the last 90 days, with the most recent on 2026-09-22. The full record for LLY runs to 179 Form 4 filings, the earliest from 2024-10-22. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying LLY stock?
No insider purchases of LLY were filed in the last 90 days. 9 purchases are on record for this company.
How many insiders are selling LLY stock?
3 insider sales of LLY were filed in the last 90 days, totaling $15.96M.
Where can I see LLY SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects LLY Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
House of Representatives Periodic Transaction Reports from 2024. Senate filings are not included yet. The full history of LLY beside its insider purchases is in the Congress Tracker.
Patrik Jonsson - OfficerOpen-market sale$7.64M
Juan R. Luciano - Director
J. Erik Fyrwald - Director
Mary Lynne Hedley - Director
Gabrielle Sulzberger - Director
Michael A. RulliRepublican, OH-06
